Login
$TELA
$0.76 -$0.06 (7.13%) Live

$TELA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 S-3
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter end...

19 Oct 2026 Form 4: Capper Joseph H, Director

Received 19,801 shares as a grant or award ($20K)

19 Oct 2026 Form 4: Plovanic William J., Director

Received 16,089 shares as a grant or award ($16.2K)

08 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’...

06 Oct 2026 8-K: Other Events

On October 5, 2026, TELA Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Mark...

05 Oct 2026 8-K: Other Events

MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug...

29 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 28, 2026, TELA Bio, Inc. (the “Company”) entered into a Limited Consent to Credit Agreement and Guaranty (the “Limited Consent”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “Admin...

18 Sep 2026 Form 4: Capper Joseph H, Director

Bought 50,000 shares ($58.3K) · Bought 25,000 shares ($30.5K)

18 Sep 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

16 Sep 2026 Form 4: Capper Joseph H, Director

Bought 25,000 shares ($25.5K) · Bought 50,000 shares ($52.9K)

14 Sep 2026 DEF 14A
04 Sep 2026 PRE 14A
31 Aug 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

Company to reduce annual operating expenses by $17.0 million or 18%

19 Aug 2026 Form 4: Getz Heather C, Director

Bought 12,500 shares ($8.31K)

17 Aug 2026 Form 4: Getz Heather C, Director

Bought 15,000 shares ($10.5K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support